Company news
Alumis Inc. news in 2026
Alumis Inc.'s news releases, calls and decks from 2026, newest first.
Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
November 12, 2026
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
October 9, 2026
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
August 14, 2026
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
August 13, 2026
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
August 10, 2026
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
May 13, 2026
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
March 27, 2026
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
March 18, 2026
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
March 17, 2026
Alumis to Present at the Leerink Partners Global Healthcare Conference
March 2, 2026
Alumis to Participate in Upcoming February Investor Conferences
February 5, 2026
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 9, 2026
Alumis Announces Pricing of Upsized Public Offering of Common Stock
January 7, 2026
Alumis Announces Proposed Public Offering of Common Stock
January 6, 2026
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
January 6, 2026
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
January 5, 2026
Decks in 2026
- Technical Presentation (September 2026)
Technical · 20 slides · Sep 1, 2026
- Investor Presentation (August 2026)
Investor deck · 37 slides · August 2026
- Investor Presentation (June 2026)
Investor deck · 36 slides · Jun 29, 2026
- Technical Presentation (May 2026)
Technical · 21 slides · May 14, 2026
- Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout Analyst and Investor Webcast (January 2026)
Conference · 25 slides · Jan 6, 2026
- Corporate Update (January 2026)
Corporate update · 25 slides · Jan 6, 2026
- Investor Presentation (2026)
Investor deck · 39 slides · 2026